Bank of Montreal Can decreased its holdings in Medpace Holdings Inc (NASDAQ:MEDP) by 11.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,909 shares of the company’s stock after selling 4,120 shares during the period. Bank of Montreal Can owned about 0.09% of Medpace worth $1,881,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. LS Investment Advisors LLC acquired a new stake in Medpace during the fourth quarter worth approximately $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new stake in Medpace during the fourth quarter worth approximately $87,000. State of Alaska Department of Revenue acquired a new stake in Medpace during the fourth quarter worth approximately $92,000. NumerixS Investment Technologies Inc acquired a new stake in Medpace during the fourth quarter worth approximately $119,000. Finally, We Are One Seven LLC acquired a new stake in Medpace during the fourth quarter worth approximately $130,000. 76.70% of the stock is currently owned by institutional investors.
MEDP has been the topic of a number of analyst reports. TheStreet raised Medpace from a “c” rating to a “b-” rating in a research report on Thursday, June 6th. BidaskClub raised Medpace from a “hold” rating to a “buy” rating in a report on Wednesday, March 20th. ValuEngine downgraded Medpace from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Zacks Investment Research raised Medpace from a “sell” rating to a “hold” rating and set a $63.00 target price on the stock in a report on Wednesday, May 1st. Finally, Robert W. Baird raised their target price on Medpace from $57.00 to $62.00 and gave the company a “neutral” rating in a report on Tuesday, April 30th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $59.25.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.04. The company had revenue of $200.70 million during the quarter, compared to analysts’ expectations of $190.16 million. Medpace had a return on equity of 17.16% and a net margin of 10.49%. Medpace’s revenue was up 23.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. As a group, equities analysts forecast that Medpace Holdings Inc will post 2.64 EPS for the current year.
In other news, General Counsel Stephen P. Ewald sold 7,946 shares of the firm’s stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $57.95, for a total value of $460,470.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jesse J. Geiger sold 12,000 shares of the firm’s stock in a transaction dated Friday, March 29th. The shares were sold at an average price of $58.20, for a total value of $698,400.00. Following the completion of the sale, the chief financial officer now owns 25,037 shares of the company’s stock, valued at $1,457,153.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,983 shares of company stock valued at $2,661,091. 24.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Bank of Montreal Can Has $1.88 Million Holdings in Medpace Holdings Inc (NASDAQ:MEDP)” was published by Tech Know Bits and is owned by of Tech Know Bits. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://techknowbits.com/2019/06/11/bank-of-montreal-can-has-1-88-million-holdings-in-medpace-holdings-inc-medp.html.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.